Lyell Immunopharma (LYEL) Assets Average (2021 - 2026)
Lyell Immunopharma (LYEL) posted Assets Average of $345.3 million for Q1 2026, down 7.67% sequentially from $374.0 million in Q4 2025, and down 24.98% YoY from $460.3 million in Q1 2025.
Lyell Immunopharma (LYEL) Assets Average (2021 - 2026) Analysis & Trends
Lyell Immunopharma has reported Assets Average for 6 years, with the latest figure at $345.3 million in Q1 2026.
- Quarterly Assets Average fell 24.98% year-over-year to $345.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $345.3 million (down 24.98% YoY) and the FY2025 annual result came in at $415.5 million, down 33.04% from the prior year.
- Assets Average fell to $345.3 million in Q1 2026 per LYEL's latest filing, from $374.0 million in the prior quarter.
- Over five years, Assets Average peaked at $1.1 billion in Q1 2022 and troughed at $345.3 million in Q1 2026.
- A 5-year average of $707.7 million and a median of $722.1 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2025: Assets Average decreased 17.34% in 2023, then tumbled 39.54% in 2025.
- Over 5 years, Assets Average stood at $957.4 million in 2022, then slipped by 19.31% to $772.5 million in 2023, then retreated by 28.15% to $555.0 million in 2024, then plunged by 32.62% to $374.0 million in 2025, then slipped by 7.67% to $345.3 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $345.3 million, $374.0 million, and $396.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | 330.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 330.89 Mn |
| Mar 31, 2026 | 345.34 Mn |
| Dec 31, 2025 | 374.01 Mn |
| Sep 30, 2025 | 396.71 Mn |
| Jun 30, 2025 | 407.63 Mn |
| Mar 31, 2025 | 460.33 Mn |
| Dec 31, 2024 | 555.04 Mn |
| Sep 30, 2024 | 636.68 Mn |
| Jun 30, 2024 | 674.18 Mn |
| Mar 31, 2024 | 722.12 Mn |
| Dec 31, 2023 | 772.51 Mn |
| Sep 30, 2023 | 815.17 Mn |
| Jun 30, 2023 | 857.90 Mn |
| Mar 31, 2023 | 909.01 Mn |
| Dec 31, 2022 | 957.42 Mn |
| Sep 30, 2022 | 999.47 Mn |
| Jun 30, 2022 | 1.05 Bn |
| Mar 31, 2022 | 1.10 Bn |
| Dec 31, 2021 | 1.16 Bn |
| Sep 30, 2021 | 1.21 Bn |